+942.5%
CRDO vs MRNA
+34.8%
+907.7%
-61.1%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.6% | +5.4% | -3.7% | +1.5% |
| 7D | -4.5% | -1.1% | -3.4% | -4.4% |
| 30D | -39.2% | +126.1% | -165.4% | -42.1% |
| 3M | -38.5% | +190.0% | -228.5% | -44.4% |
| 6M | +40.6% | +157.2% | -116.6% | +29.2% |
| YTD | +13.2% | +388.2% | -375.0% | -7.6% |
| 1Y | +2.3% | +467.0% | -464.8% | -19.4% |
| 3Y | +942.5% | +36.1% | +906.5% | +803.2% |
| All | +942.5% | +34.8% | +907.7% | +803.2% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling